Lab equity participation: when a buy-in offer is actually worth it

Group lab buy-in offers come with valuations, K-1 income, and exit timing. Here’s the framework before you write the check.

As a physician, your first partnership buy-in offer feels like a milestone. It is. But it’s also one of the most complex financial decisions you’ll ever make. The offer sheet might focus on a valuation multiple and a projected income, but the real value—or risk—is buried in the structure. This is especially true in capital-intensive fields like laboratory medicine, pathology, and diagnostic imaging, where multi-million dollar equipment and real estate are the core assets.

Most of us learn this the hard way: by looking at a K-1 in year three and wondering why we owe six figures in tax on “phantom income” we never actually received. The difference between a career-defining investment and a decade-long financial drag comes down to understanding the tax and operational levers that drive the partnership’s real returns. This isn’t about timing the market; it’s about understanding the machinery. For a broader look at the operational side of our field, see the full laboratory medicine hub for more resources.

Here’s the physician-to-physician breakdown of the five key financial structures you must evaluate before you sign that buy-in agreement.

The Power Couple: Section 179 and Bonus Depreciation on Heavy Iron

When I look at a partnership that owns its own equipment—whether it’s a high-throughput chemistry analyzer, a digital pathology scanner, or a 3T MRI—the first thing I check is how they handle depreciation. For a capital-intensive lab or imaging center, this is the single most powerful tool for reducing partners’ taxable income.

The strategy hinges on two parts of the tax code: Section 179 and bonus depreciation. Think of them as a one-two punch for accelerating tax deductions.

Section 179 allows a business to treat the cost of qualifying equipment as an immediate expense rather than capitalizing it and depreciating it over many years. For 2026, the deduction limit is a substantial $1.16 million. This means if your partnership buys a new piece of equipment for $1 million, it can potentially deduct the entire amount from its income in the year it was placed in service.

Bonus Depreciation picks up where Section 179 leaves off. It allows for an additional first-year deduction on the cost of new and used equipment. The percentage for bonus depreciation is scheduled to phase down—for 2026, it’s 20%—but it still provides a significant upfront benefit on assets costing more than the Section 179 limit.

Let’s run a concrete example. Your pathology group decides to purchase a new digital scanning and AI analysis suite for $2 million.

• You expense the first $1.16 million under Section 179.
• On the remaining $840,000, you take 20% bonus depreciation in 2026, which is another $168,000 deduction.
• The remaining basis is depreciated over its normal useful life (typically 5 or 7 years).

The result? In year one, the partnership generates a $1,328,000 non-cash deduction ($1.16M + $168k). This massive “paper loss” flows through to the partners on their K-1s, directly reducing their taxable income from the practice. For a new partner, this can mean a near-zero tax bill from partnership income in the first year, freeing up cash flow to pay down the buy-in note.

The Trap to Avoid: The Section 179 deduction cannot create a net loss for the business; it’s limited to the business’s net income. However, any unused amount can be carried forward. The bigger trap is recapture. If the partnership sells that equipment before its useful life is up, the IRS may require you to “recapture” the depreciation, meaning you’ll have to pay back the tax benefit as ordinary income. This is a critical question to ask about the partnership’s equipment lifecycle and upgrade plans.

The QBI Workaround: Using an Equipment Leasing Company for 199A

One of the most valuable tax deductions for small businesses is the Section 199A Qualified Business Income (QBI) deduction, which allows owners of pass-through entities to deduct up to 20% of their qualified business income. There’s a catch for physicians: medical practices are considered a “Specified Service Trade or Business” (SSTB). This means the QBI deduction is phased out and ultimately eliminated for partners with taxable income above certain thresholds—thresholds that most practicing physicians easily exceed.

This is where sophisticated practice structuring comes in. A common and effective strategy is to separate the high-value equipment from the medical practice itself.

Here’s the sequence:

1. The partners form a separate legal entity, typically an LLC, that is not the medical practice. Let’s call it “LabCo Holdings, LLC.”
2. LabCo Holdings, LLC purchases the expensive lab or imaging equipment.
3. LabCo Holdings then executes a formal, long-term lease agreement to lease the equipment to the medical practice at a fair market rate.

Why does this work? An equipment leasing business is generally not considered an SSTB. Therefore, the net rental income generated by LabCo Holdings can qualify for the full 20% QBI deduction, even for high-income physician owners. This effectively allows the partners to “move” a portion of the practice’s profit into a QBI-eligible entity, restoring a tax benefit that would otherwise be lost.

The Trap to Avoid: This is not a casual arrangement. To be respected by the IRS, it must be structured correctly. The lease rates must be commercially reasonable and defensible—you can’t just invent a number to shift profits. Furthermore, the entities often need to be formally “aggregated” for tax purposes under specific rules in Treasury Regulation §1.199A-4, which requires, among other things, significant common ownership (typically 50% or more). Setting this up without a CPA who has deep experience in physician practice structuring is a recipe for an audit finding.

Deconstructing the K-1: The Real Economics of an Outpatient Center

When you buy into an outpatient lab or imaging center, your return isn’t a salary; it’s a Schedule K-1. This single form is the summary of your pro-rata share of the business’s income, deductions, credits, and distributions. Learning to read it is like learning to interpret a CT scan—the key findings aren’t always the most obvious ones.

The two most important numbers on your K-1 are often in conflict:

• Box 1: Ordinary Business Income. This is your share of the partnership’s taxable profit. Thanks to the massive depreciation deductions we discussed, this number can be surprisingly low, or even a large loss, in the early years of a new center.
• Box 19: Distributions. This is the actual cash the partnership paid out to you.

In year one, it’s common to see a large distribution (cash in your pocket) but a large tax loss in Box 1 (no tax due). This is the magic of depreciation. However, the tables eventually turn. As depreciation deductions wane over the years, the taxable income in Box 1 will rise. If the partnership is using its cash flow to pay down the principal on its equipment loans, your cash distributions might stay flat or even decrease.

This leads to the dreaded “phantom income” trap. You might receive a K-1 showing $200,000 in taxable income but only have received $120,000 in cash distributions. You still owe federal and state tax on the full $200,000. If you’re not prepared, this can create a sudden and severe cash flow crisis.

A smart buy-in analysis involves modeling this out. Ask for the center’s depreciation schedule and debt amortization schedule. Project when the “flip” will happen—the point where taxable income begins to consistently exceed cash distributions. A good partnership agreement will often include a provision for “tax distributions” to ensure partners receive enough cash to cover the tax liability on their allocated income. If it doesn’t, that’s a major red flag.

When you’re evaluating the buy-in price, don’t just look at last year’s EBITDA. Use a margin of safety calculator to discount future projected cash flows, not just accounting profits. The cash you can actually use is what pays your mortgage.

Front-Loading Deductions with Cost Segregation on the Facility

If the partnership owns the building that houses the lab or imaging center, there’s another powerful tax strategy that works in tandem with equipment depreciation: cost segregation.

By default, the IRS considers a commercial building to be “39-year property,” meaning you get to deduct its cost evenly over 39 years. A cost segregation study is an engineering-based analysis that meticulously identifies all the components of a building that can be legally reclassified into shorter-lived asset classes.

Here’s what a study typically finds:

• 5-Year Property: Carpeting, specialty electrical wiring for equipment, decorative lighting, cabinetry, and other non-structural finishes.
• 7-Year Property: Office furniture and certain fixtures.
• 15-Year Property: Land improvements like parking lots, sidewalks, and landscaping.

The goal is to move as much of the building’s cost as possible from the 39-year bucket into these 5, 7, and 15-year buckets. Why? Because these shorter-lived assets are also eligible for bonus depreciation.

Consider a $3 million facility. A typical cost segregation study might reclassify 25% of the cost ($750,000) into 5 and 15-year property. In a year with 100% bonus depreciation, the partnership could deduct that entire $750,000 in year one, instead of spreading it over decades. Even with the 2026 bonus depreciation rate of 20%, that’s an extra $150,000 first-year deduction. This turbocharges the tax-shelter effect in the early years of ownership, dramatically improving the internal rate of return on the investment.

The Trap to Avoid: A cost segregation study is not something your regular accountant does. It must be performed by a specialized engineering firm that can produce a detailed, defensible report that will stand up to IRS scrutiny. A low-quality, “rule-of-thumb” study is a huge audit risk. When evaluating a buy-in, ask if a formal cost segregation study has been performed on the property. If not, it represents a significant untapped financial opportunity.

The S-Corp Advantage: Slashing Self-Employment Tax

For partners who are not W-2 employees of the practice—common in many modern partnership structures—or for independent physicians, structuring your professional income through an S-corporation can yield significant tax savings.

When you operate as a sole proprietor or a member of a standard LLC, all of your net business income is subject to self-employment (SE) taxes. This consists of 12.4% for Social Security (up to the annual wage base, $168,600 in 2024) and 2.9% for Medicare (uncapped). That’s a 15.3% tax hit on a substantial portion of your income before you even get to federal and state income taxes.

An S-corp allows you to split your income into two categories:

1. Reasonable Salary: The S-corp must pay you, the owner-employee, a reasonable salary via a W-2. This salary is subject to the same FICA taxes (the employee and employer share of Social Security and Medicare) as any other W-2 job.
2. Distributions: Any remaining profit from the business can be paid out to you as a shareholder distribution. This distribution is not subject to SE or FICA taxes.

The savings come from the tax differential on the distribution portion. For every $100,000 you can legitimately classify as a distribution instead of salary, you save up to $15,300 in SE taxes (or $2,900 if you’re already over the Social Security wage base).

The Trap to Avoid: The key phrase here is “reasonable salary.” The IRS is very clear that you cannot pay yourself an artificially low salary (e.g., $30,000) and take the rest as a distribution to avoid payroll taxes. Your W-2 salary must be a defensible figure that reflects what someone in your specialty, with your experience, in your geographic area would earn for the work you perform. There are databases and compensation studies that can help establish this figure. Setting an unreasonably low salary is one of the fastest ways to trigger an IRS audit. This strategy requires careful planning with a CPA to determine and document a reasonable compensation level.

—

Evaluating a lab or imaging center buy-in requires looking beyond the surface-level valuation. The underlying tax structure, asset management, and entity choice can have a greater impact on your net, after-tax return than the purchase price itself. By understanding these five core concepts, you can ask the right questions and analyze the offer not just as a clinician, but as a sophisticated investor. If the diligence process feels overwhelming or the answers from the group are unclear, it may be time to request a diligence memo on a buy-in to get an independent, data-driven analysis of the opportunity.

Free GigHz Tools That Pair With This Article

Three free tools that complement the material above:

• ACR Appropriateness Criteria Lookup — Type an indication or clinical scenario in plain language and get the imaging studies the ACR rates for it, with adult and pediatric radiation levels. Built directly from 297 ACR topics, 1,336 clinical variants, and 15,823 procedure ratings.
• GigHz Imaging Protocol Library — A searchable library of 131 imaging protocols with the physics specs surfaced and the matching ACR Appropriateness Criteria alongside. Plain-English narratives readable in 60 seconds, organized by modality.
• GigHz Radiation Dose Calculator — Pick the imaging studies a patient has had and see total dose in millisieverts (mSv) with comparisons to natural background radiation, transatlantic flights, and chest X-rays. Useful for shared decision-making.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026